Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ß-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

2018
https://researcherprofiles.org/profile/20118073
30012675
Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group